Monte Rosa Therapeutics, Inc. (GLUE) News
Track canonical SquawkNews coverage tagged to GLUE, Monte Rosa Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 14 indexed stories across 10 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
Monte Rosa Therapeutics Reports Positive Phase 1 MRT-8102 Data
Monte Rosa Therapeutics announced positive GFORCE-1 Phase 1 results for MRT-8102, demonstrating approximately 80-90% NEK7 degradation and broad normalization of ASCVD pathogenic drivers, accompanied by a favorable safety
EQUITY | Oct 01, 2026, 11:43 AM UTC
H
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Shares of Vicor Corp (NASDAQ: VICR ) rose sharply in pre-market trading after the company raised its third-quarter sequential revenue growth guidance. Vicor raised its third-quarter sequential revenue growth guidance to
LIVE | Oct 01, 2026, 08:31 AM UTC
H
TABLE-Mrt -2026 div forecast
Sept 30 (Reuters) -Mrt Inc.CONSOLIDATED EARNINGS ESTIMATES(in billions of yen unless specified)Full year to Full year toDec 31, 2026 Dec 31, 2026LATEST PREVIOUSFORECAST FORECASTAnnual Div 5.00 yen NIL-Q2 Div NIL-Q4 Div…
EARNINGS | Sep 30, 2026, 07:01 AM UTC
L
Wedbush keeps Monte Rosa Therapeutics price target at $27.00
Wedbush maintained its $27.00 per-share price target for Monte Rosa Therapeutics, according to ratings actions cited by Benzinga (via TradingView News).
EQUITY | Sep 09, 2026, 12:22 PM UTC
M
Monte Rosa gets $50 million milestone as Novartis starts Phase 2
Monte Rosa said it received a $50 million milestone payment after Novartis started a Phase 2 study of MRT-6160, also known as DDY391, in Sjögren’s disease.
REGULATION | Sep 08, 2026, 11:03 AM UTC
M
GLUE: Monte Rosa starts Phase 2 study of MRT-6160
GLUE-linked disclosure says Monte Rosa Therapeutics has initiated a Phase 2 clinical study for its VAV1-directed molecular glue degrader MRT-6160 (DDY391).
EQUITY | Sep 08, 2026, 11:00 AM UTC
L
Monte Rosa reports inducement grants under Nasdaq Rule 5635(c)(4)
Monte Rosa Therapeutics, Inc. says it has reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:14 PM UTC
L
GLUE/Monte Rosa reports Nasdaq Rule 5635(c)(4) inducement grants
GLUE says Monte Rosa reported inducement grants under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Monte Rosa Therapeutics management to participate in investor conferences
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) said management will participate in upcoming investor conferences, with a webcast of the fireside chat planned.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
GLUE: Monte Rosa Therapeutics to participate in investor conferences
Monte Rosa Therapeutics plans to participate in upcoming investor conferences.
EQUITY | Sep 01, 2026, 11:00 AM UTC
L
Monte Rosa Therapeutics doses first patient in Phase 2 prostate study
Monte Rosa Therapeutics announces first patient dosed in MODeFIRe-1, a Phase 2 study of MRT-2359 in combination with apalutamide in AR mutation-positive metastatic castration-resistant prostate cancer.
EQUITY | Aug 24, 2026, 11:00 AM UTC
L
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
GLUE - Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
EARNINGS | Aug 06, 2026, 11:00 AM UTC
L
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
GLUE PT raised from $30 to $40, maintains Buy @ JEFF
EQUITY | Jul 27, 2026, 01:20 PM UTC
L
Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ: GLUE ) with a Buy and raises the price target from $30 to $35.
EQUITY | Jun 30, 2026, 01:54 PM UTC